IgA EGFR antibodies mediate tumour killing in vivo
نویسندگان
چکیده
Currently all approved anti-cancer therapeutic monoclonal antibodies (mAbs) are of the IgG isotype, which rely on Fcgamma receptors (FcγRs) to recruit cellular effector functions. In vitro studies showed that targeting of FcαRI (CD89) by bispecific antibodies (bsAbs) or recombinant IgA resulted in more effective elimination of tumour cells by myeloid effector cells than targeting of FcγR. Here we studied the in vivo anti-tumour activity of IgA EGFR antibodies generated using the variable sequences of the chimeric EGFR antibody cetuximab. Using FcαRI transgenic mice, we demonstrated significant in vivo anti-tumour activity of IgA2 EGFR against A431 cells in peritoneal and lung xenograft models, as well as against B16F10-EGFR cells in a lung metastasis model in immunocompetent mice. IgA2 EGFR was more effective than cetuximab in a short-term syngeneic peritoneal model using EGFR-transfected Ba/F3 target cells. The in vivo cytotoxic activity of IgA2 EGFR was mediated by macrophages and was significantly decreased in the absence of FcαRI. These results support the potential of targeting FcαRI for effective antibody therapy of cancer.
منابع مشابه
IgA EGFR antibodies mediate tumor killing in vivo
Thank you for the submission of your manuscript "IgA EGFR antibodies mediate tumor killing in vivo" to EMBO Molecular Medicine. We have now heard back from the three referees whom we asked to evaluate your manuscript (please see the attached PDF for a formatted report of Reviewer 3). You will see that they find the topic of your manuscript potentially interesting. However, they also raise signi...
متن کاملSimultaneous Targeting of FcgRs and FcaRI Enhances Tumor Cell Killing
Efficacy of anticancer monoclonal antibodies (mAb) is limited by the exhaustion of effector mechanisms. IgG mAbs mediate cellular effector functions through FcgRs expressed on effector cells. IgAmAbs can also induce efficient tumor killing both in vitro and in vivo. IgA mAbs recruit FcaRI-expressing effector cells and therefore initiate different effector mechanisms in vivo compared with IgG. H...
متن کاملSimultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
Efficacy of anticancer monoclonal antibodies (mAb) is limited by the exhaustion of effector mechanisms. IgG mAbs mediate cellular effector functions through FcγRs expressed on effector cells. IgA mAbs can also induce efficient tumor killing both in vitro and in vivo. IgA mAbs recruit FcαRI-expressing effector cells and therefore initiate different effector mechanisms in vivo compared with IgG. ...
متن کاملMonoclonal Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro and In Vivo Killing of African Invasive Nontyphoidal Salmonella
Nontyphoidal Salmonella (NTS), particularly Salmonella enterica serovars Typhimurium and Enteritidis, is responsible for a major global burden of invasive disease with high associated case-fatality rates. We recently reported the development of a candidate O-antigen-CRM197 glycoconjugate vaccine against S. Typhimurium. Here, using a panel of mouse monoclonal antibodies generated by the vaccine,...
متن کاملBispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE®), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for treating certain CD19-positive hematological malignancies. In contrast, solid tumors with heteroge...
متن کامل